The market share fight for the newest class of cardiovascular drugs saw Thousand Oaks, California–based Amgen win a legal skirmish in March when a US District Court jury upheld two of its patents covering monoclonal antibodies against PCSK9. Defendants Regeneron Pharmaceuticals and partner Sanofi admitted that their cholesterol drug Praluent (alirocumab) infringed claims in both patents, but argued that the patents were invalid. Regeneron, of Tarrytown, New York, and Paris-based Sanofi plan to appeal the decision to the US Court of Appeals for the Federal Circuit. In a statement, Sanofi and Regeneron said, “This decision is the first step in this ongoing litigation and does not impact Praluent or our ability to deliver it to physicians and patients at this time.” Amgen markets its own PCSK9 drug, Repatha (evolocumab), which was approved by the Food and Drug Administration in August 2015, one month after Praluent. However, instead of damages or royalties, Amgen has requested a permanent injunction on sales of Praluent, which would leave Repatha as the sole PCSK9 drug on the market—for the time being. Last month, Pfizer's PCSK9 inhibitor cleared its second phase 3 trial, setting up a possible regulatory filing in the coming months. If it reaches the market, bococizumab could compete with Repatha and Praluent.